MEDVi vs Noom (2026):
All-Inclusive Care vs. Behavioral Coaching

The One-Minute Summary

Side-by-Side Comparison

The Biggest Difference: What You Are Actually Paying For

The core philosophical difference between MEDVi and Noom is what each platform believes causes obesity — and therefore what it is selling you.

MEDVi: Medication Is the Solution

MEDVi is a pure medical delivery platform. Their model is: get you the right GLP-1 medication quickly, at a predictable price, with 24/7 clinical support. They do not offer behavioral coaching, psychology lessons, or community features. The implicit belief is that the medication itself — by suppressing appetite and regulating hunger hormones — is sufficient to produce meaningful weight loss when properly prescribed and monitored.

This is well-supported by clinical evidence. The STEP trials showed 15–17% average body weight loss on semaglutide 2.4mg without any specific behavioral intervention. MEDVi’s approach is clinically sound.

Noom: Behavior Is the Root Cause

Noom’s model is fundamentally different. They believe that the reason most people regain weight after stopping any intervention — including GLP-1 medications — is that the underlying behavioral patterns and psychological relationship with food have not changed. Their platform was built on this premise a decade before they added GLP-1 prescriptions.

The Noom app includes daily psychology-based lessons, food logging, a personal coach, and a community of other users. The GLP-1 prescription is positioned as a tool to reduce the biological drive to overeat while the behavioral work addresses the psychological drivers. In theory, this combination should produce more durable results after stopping medication.

The problem is the dose cap. Noom’s Microdose program limits semaglutide to 0.6mg weekly — well below the 1.0–2.4mg doses that produce the most significant weight loss in clinical trials. Many patients report minimal appetite suppression at this dose, which undermines the entire model.

The Noom Microdose Problem

This is the most important thing to understand about Noom’s GLP-1 program, and it is the reason their customer service reviews are so consistently negative despite the quality of their coaching app.

Noom’s Microdose program caps semaglutide at 0.6mg weekly. The clinical evidence is unambiguous: at doses below 0.5mg, most patients experience minimal to no meaningful appetite suppression or weight loss. The dose-response relationship in GLP-1 therapy is well-established — you need to reach at least 0.5mg, and ideally 1.0mg or higher, to see significant results.

Patients who enroll in the Microdose program expecting the appetite suppression they have heard about from friends and social media are frequently disappointed. The behavioral coaching is excellent — but it is much harder to change your relationship with food when the medication is not providing the biological support it is supposed to.

Noom does offer a standard clinical dose program at $299/month, which does not have the dose cap. If you are committed to Noom’s coaching approach, the standard program is significantly more likely to produce results than the Microdose.

MEDVi’s Dose Advantage

MEDVi prescribes compounded semaglutide at full clinical doses — starting at 0.25mg and escalating to 2.4mg as tolerated. There is no artificial cap. Patients who reach maintenance doses of 1.0–2.4mg typically experience strong appetite suppression, which is the primary mechanism of GLP-1 weight loss. MEDVi also offers compounded tirzepatide, which Noom does not.

Pricing: Closer Than It Looks

At first glance, Noom appears cheaper. The Microdose program starts at $199/month versus MEDVi’s $179 introductory month. But once you move past the first month, the comparison shifts.

MEDVi’s ongoing rate is approximately $299–$399/month depending on dose tier. Noom’s standard clinical dose program is $299/month. At that level, they are essentially the same price — but MEDVi includes 24/7 care team access and a money-back guarantee, while Noom includes the behavioral coaching app.

The Noom Microdose at $199/month is cheaper, but as discussed above, the dose cap makes it significantly less likely to produce meaningful weight loss for most patients. The lower price comes with a meaningful clinical trade-off.

Who Gets Better Value?

If you are going to pay $299/month regardless of which platform you choose, MEDVi delivers more clinical value per dollar: full clinical doses, tirzepatide access, 24/7 support, and a money-back guarantee. Noom at $299/month delivers more behavioral support per dollar: daily coaching, psychology lessons, community, and a food logging system.

The question is which of those two things you actually need more.

Who Should Choose Each Platform

Choose MEDVi If:

• You want fast, reliable access to GLP-1 medication at full clinical doses with no artificial cap
• 24/7 care team access is important to you — you want to reach someone at any hour
• You want tirzepatide as an option alongside semaglutide
• You want predictable all-inclusive billing with a money-back guarantee
• You have tried behavioral approaches before and believe the medication is the primary intervention you need

Choose Noom If:

• You believe your relationship with food and eating habits are the root cause of your weight challenges — and you want to address that alongside the medication
• You are committed to the standard clinical dose program ($299/mo) rather than the Microdose — the coaching is only effective when the medication is working
• You want a structured daily app experience with lessons, food logging, and community
• You have tried GLP-1 medications before without behavioral support and regained weight after stopping

Our Verdict

MEDVi and Noom are genuinely different products serving genuinely different patients. MEDVi wins on clinical efficiency — full doses, fast delivery, 24/7 support, tirzepatide access, and a money-back guarantee. Noom wins on behavioral depth — the coaching app is the best in the industry and the psychology-based approach has a decade of evidence behind it.

The critical caveat for Noom is the Microdose dose cap. If you choose Noom, choose the standard $299/month program — not the Microdose. The coaching is only effective when the medication is providing meaningful appetite suppression, and 0.6mg is not enough for most patients.

If you are still undecided, neither MEDVi nor Noom is the cheapest option in the market. Mochi Health offers flat-rate pricing at ~$178/month with full clinical doses, and Yucca Health offers $146/month on a 6-month plan with a B12 boost and onboarding call.

Affiliate Disclosure: TheDoseReport.com participates in affiliate programs. Some links on this site may earn us a commission at no extra cost to you. This does not influence our editorial content. All reviews and opinions are our own.

Medical Disclaimer: This website does not provide medical advice. All content is for informational purposes only. Always consult a qualified healthcare professional before starting any weight loss program or medication.